This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ABO-102

Abeona Therapeutics, Inc.

Drug Names(s): ABX-A, AAV-SGSH, ABO102

Description: ABX-A is a gene therapy in development for Sanfilippo (SF) Syndrome Type A. It consists of recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase. Deficiency of the enzyme leads to buildup of heparan sulfate.

Deal Structure: Abeona and PlasmaTech
In May 2015, PlasmaTech entered into a definitive agreement to acquire Abeona. ABX-A was originally developed by Abeona. Under the terms of the agreement, the Company will issue to Abeona Therapeutic members a total of 3,979,761 common shares upon closing of the transaction, and up to an additional $9 million in performance milestones, in common stock or cash, at the Companys option.

In May 2015, PlasmaTech Biopharmaceuticals completed its acquisition of Abeona Therapeutics pursuant to the terms of an Agreement and Plan of Merger.


ABO-102 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug